The DOI matches its Crossref record, with a small difference in title or year; 1 of the 1 references it cites were found in a registry or an index.
Counting the Cost of Meningococcal Disease: Scenarios of Severe Meningitis and Septicemia
Abstract
Background Meningococcal disease can result in severe disabling sequelae, but there is no published information about the lifelong rehabilitation costs of patients with severe outcome in the UK. As cost-effectiveness studies play a crucial role in determining whether immunization programmes will be implemented, it is important to identify these costs. Objective The aim of the study was to estimate lifelong rehabilitation costs associated with severe cases of meningococcal disease and to present these costs in a format appropriate for use in a cost-effectiveness analysis. Methods Two severe scenarios of meningococcal disease with major sequelae were developed; one that presented acutely as meningitis and the other as septicemia. Scenarios were based on systematic reviews of the literature describing the sequelae of meningococcal disease, dialogue with Meningitis Research Foundation members who have experience of the disease, and discussions with pediatricians who have been responsible for managing children with this disease over many years. The two scenarios were devised to represent cases typical of the severe end of the spectrum. To obtain a comprehensive list of the health, educational and other resources used by survivors during and since their acute illness, families of individuals with sequelae similar to those in each of our scenarios were interviewed. Relevant academics and professionals in health, social care and education were consulted in order to ensure that our sc…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, the costs associated with these infections are significant, both in the short term related to hospitalization and treatment and in the long-term related to lost contributions to society (3, 4).”
From Multicenter Evaluation of BioFire FilmArray Meningitis/Encephalitis Panel for Detection of Bacteria, Viruses, and Yeast in Cerebrospinal Fluid Specimens (2016) · cites this paper as [3]
Citations
Cites
Edmond, K., Clark, A., Korczak, V. S., Sanderson, C., Griffiths, U. K., & Rudan, I. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70048-7 · Cited by 631
Research works printed but not linked: 11
- Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990–1994. Clin Infect Dis. 1998;26(5):1159–64. · DOI
- Canavese F, Krajbich JI, LaFleur BJ. Orthopaedic sequelae of childhood meningococcemia: management considerations and outcome. J Bone Joint Surg Am. 2010;92(12):2196–203. · DOI
- Hall AJ. The United Kingdom Joint Committee on Vaccination and Immunisation. Vaccine. 2010;28(Suppl 1):A54–7. · DOI
- Trotter CL, Edmunds WJ. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. BMJ. 2002;324:809. · DOI
- Ten Jonsson B. Arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ. 2009;10(4):357–9. · DOI
- Treasury HM. The green book: appraisal and evaluation in central government. London: TSO; 2003.
- Buysse CM, et al. Long-term health status in childhood survivors of meningococcal septic shock. Arch Pediatr Adolesc Med. 2008;162(11):1036–41. · DOI
- Welte R, et al. The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine. Pharmacoeconomics. 2005;23(9):855–74. · DOI
- Gordon D, Parker R, Loughran F, Heslop P. Disabled children in Britain: a re-analysis of the OPCS disability survey. London: The Stationery Office; 2000.
- Cadman D, Boyle M, Offord DR. The Ontario Child Health Study: social adjustment and mental health of siblings of children with chronic health problems. J Dev Behav Pediatr. 1988;9(3):117–21. · DOI
- Viner RM, et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11(9):774–83. · DOI
Cited by
Sorted by citations
Leber, A. L., Everhart, K., Balada-Llasat, J.-M., Cullison, J., Daly, J., Holt, S., Lephart, P., Salimnia, H., Schreckenberger, P. C., DesJarlais, S., et al. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.00730-16 · Cited by 609
Real‐World Evaluation of the BioFire FilmArray ME Panel: Diagnostic Accuracy and Clinical Utility
Erinmez, M., Sağlam, M., Çalışkantürk, G., Özerol, M., & Zer, Y. (2026) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/cjid/3714674 · Cited by 1
Metadata
- Authors
- Wright, C., Wordsworth, R., & Glennie, L.
- Affiliations
- Meningitis Research Foundation (GB)
- Corresponding author
- Wright, Claire
- ORCID
- Wright, Claire
- Venue
- Pediatric Drugs
- Published
- 2013-01-16
- Volume
- 15
- Issue
- 1
- Pages
- 49-58
- ISSN
- 1174-5878 (ISSN-L)
- 1179-2019
- OpenAlex
- W25177459
- Cited by
- 36
- References
- 1
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 6 · 2018: 5 · 2016: 3 · 2015: 4 · 2014: 5 · 2013: 2
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Pediatric Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- GlaxoSmithKline
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Physical Sciences › Engineering › Building and Construction › Life Cycle Costing Analysis
- Keywords
- meningococcal disease, long-term sequelae, cost estimation, meningitis, septicemia, cost-effectiveness, disability, educational costs, social care costs, health care costs, NHS perspective, government perspective
- MeSH terms
- Analysis of Variance, Cost-Benefit Analysis, Costs and Cost Analysis, United Kingdom, Humans, Meningitis, Meningococcal, Sepsis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Counting the Cost of Meningococcal Disease: Scenarios of Severe Meningitis and Septicemia. https://app.cochat.ai/papers/10.1007/s40272-012-0006-0
- The paper
- Wright, C., Wordsworth, R., & Glennie, L. (2013). Counting the Cost of Meningococcal Disease: Scenarios of Severe Meningitis and Septicemia. Pediatric Drugs. https://doi.org/10.1007/s40272-012-0006-0